ELI Radiopharma completes Angel+ Round raising over RMB 100 million to accelerate R&D and clinical translation

September 25, 2025, Hangzhou ELI Radiopharma Co., Ltd. ("ELI Radiopharma"), an innovative radiopharmaceutical company focused on developing integrated diagnostics and therapeutics for oncology and neurological diseases, announced the recent completion of an Angel+ financing round exceeding RMB 100 million. This round was co-led by Huaige Capital, CTS Capital, and KHK Fund. The proceeds will be primarily allocated to accelerate the Investigational New Drug (IND) application and early-stage clinical development of its core pipeline candidates, concurrently supporting the establishment of high-standard R&D centers and technology platforms, as well as the recruitment of top-tier R&D talent.

Months ago, ELI Radiopharma had already completed a RMB 100 million Angel financing round. The successful closure of two consecutive financing rounds fully demonstrates investors' strong recognition of the company's development strategy, R&D capabilities, and long-term value. ELI Radiopharma is committed to developing precise "theranostic" radiopharmaceuticals for oncology and neurological diseases. Leveraging its integrated capabilities in radiopharmaceutical ligand discovery, molecular optimization, and clinical translation, the company aims to advance multiple drug candidates rapidly into clinical stages, providing a new generation of diagnostic and therapeutic solutions for patients.

Dr. Feng Yu, Founder and CEO of ELI Radiopharma, stated, "We sincerely appreciate our investors' recognition and support for the company's value and long-term development. This financing round represents a significant milestone for the company and will empower ELI Radiopharma to accelerate the clinical translation of our core pipeline. We will continue to deepen our 'One Body, Two Wings' strategy, which entails simultaneously advancing the construction of our R&D centers and technology platforms while systematically building a high-caliber, highly capable core team to provide a solid foundation for strategic execution. Moving forward, we will remain steadfastly guided by clinical needs, steadily advancing the development of innovative radiopharmaceuticals, and committed to providing more precise and effective treatment options for patients with cancer and neurological diseases."